Vorinostat for GVHD Prevention

A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
49 patients (estimated)
Sponsors
University of Michigan Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
Tags
Allogeneic Stem Cell Transplant, Chemotherapy, Histone Deacetylase (HDAC) Inhibitor
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1659
NCT Identifier
NCT03842696

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.